Paper Details
- Home
- Paper Details
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Author: FaureN, FazekasA T, JeanC, LarocheB, LemayA, PlanteR, RobertG, RoyR, ThabetM
Original Abstract of the Article :
We have used the paradoxical antigonadal effects of LHRH agonists as a chemical castration in advanced prostatic cancer. We report early results of a phase II study on the clinical efficacy of the LHRH agonist D-Ser (TBU)6, des-Gly-NH2(10) LHRH administered to patients with stage D prostatic carcino...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1002/pros.2990040607
データ提供：米国国立医学図書館（NLM）
Androgen Inhibition: A New Oasis in the Desert of Prostatic Carcinoma
Prostatic carcinoma, a type of cancer that affects men, is like a vast and unforgiving desert, where researchers are constantly searching for new ways to combat this disease. This study explores the potential of androgen inhibition, using LHRH agonists and antiandrogens, as a treatment for prostatic carcinoma.
The researchers conducted a phase II clinical trial to evaluate the efficacy of an LHRH agonist, D-Ser (TBU)6, des-Gly-NH2(10) LHRH, alone or in combination with an antiandrogen, RU 23908. They assessed the impact of these treatments on testosterone levels, clinical outcomes, and side effects.
Androgen Inhibition: A Potential Weapon in the Fight Against Prostatic Carcinoma
The results of this study offer a promising glimpse into the potential of androgen inhibition for treating prostatic carcinoma. The researchers found that LHRH agonist therapy effectively suppressed testosterone levels and led to improvements in clinical outcomes in some patients.
Navigating the Shifting Sands of Prostatic Carcinoma Treatment
This research highlights the need for continued exploration of androgen inhibition as a treatment strategy for prostatic carcinoma. The researchers emphasize the importance of further studies to optimize treatment regimens and understand the long-term benefits and risks of androgen inhibition.
Dr.Camel's Conclusion
This study showcases the potential of androgen inhibition as a valuable tool in the fight against prostatic carcinoma. The researchers' findings offer hope for patients seeking effective treatments for this challenging disease. This research, like a camel caravan navigating a treacherous desert, reminds us that persistence, innovation, and collaboration are essential in the quest for new therapies that can improve the lives of patients facing this devastating disease.
Date :
- Date Completed 1983-12-17
- Date Revised 2019-09-13
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.